Luisa Bellu

1.2k total citations · 1 hit paper
43 papers, 690 citations indexed

About

Luisa Bellu is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Luisa Bellu has authored 43 papers receiving a total of 690 indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Genetics, 23 papers in Pulmonary and Respiratory Medicine and 9 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Luisa Bellu's work include Glioma Diagnosis and Treatment (34 papers), Brain Metastases and Treatment (15 papers) and Meningioma and schwannoma management (8 papers). Luisa Bellu is often cited by papers focused on Glioma Diagnosis and Treatment (34 papers), Brain Metastases and Treatment (15 papers) and Meningioma and schwannoma management (8 papers). Luisa Bellu collaborates with scholars based in Italy, United States and Austria. Luisa Bellu's co-authors include Giuseppe Lombardi, Vittorina Zagonel, Ardi Pambuku, Alessandro Della Puppa, Miriam Farina, Marina Paola Gardiman, Domenico D’Avella, Ivan Lolli, Simona Rizzato and Francesco Pasqualetti and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Luisa Bellu

41 papers receiving 683 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial

2018 257 citations Giuseppe Lombardi, Gian Luca De Salvo et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Luisa Bellu Italy	13	465	218	162	158	128	43	690
Ardi Pambuku Italy	11	451 1.0×	167 0.8×	174 1.1×	190 1.2×	130 1.0×	27	648
Myra E. van Linde Netherlands	14	365 0.8×	157 0.7×	219 1.4×	154 1.0×	188 1.5×	34	719
Yong Cui China	17	367 0.8×	272 1.2×	168 1.0×	169 1.1×	196 1.5×	59	831
Marta Peñas-Prado United States	16	627 1.3×	264 1.2×	231 1.4×	174 1.1×	141 1.1×	68	861
Ugonma Chukwueke United States	14	370 0.8×	266 1.2×	228 1.4×	122 0.8×	174 1.4×	48	798
Kirsten Grunnet Denmark	14	494 1.1×	179 0.8×	151 0.9×	166 1.1×	76 0.6×	25	588
Haihui Jiang China	17	515 1.1×	163 0.7×	139 0.9×	177 1.1×	98 0.8×	55	701
Mario Caccese Italy	17	450 1.0×	224 1.0×	253 1.6×	211 1.3×	242 1.9×	70	883
Wolfgang Wick Germany	10	312 0.7×	136 0.6×	252 1.6×	150 0.9×	112 0.9×	17	665
Pavel Šlampa Czechia	15	403 0.9×	340 1.6×	200 1.2×	197 1.2×	184 1.4×	92	916

Countries citing papers authored by Luisa Bellu

Since Specialization

Citations

This map shows the geographic impact of Luisa Bellu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luisa Bellu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luisa Bellu more than expected).

Fields of papers citing papers by Luisa Bellu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luisa Bellu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luisa Bellu. The network helps show where Luisa Bellu may publish in the future.

Co-authorship network of co-authors of Luisa Bellu

This figure shows the co-authorship network connecting the top 25 collaborators of Luisa Bellu. A scholar is included among the top collaborators of Luisa Bellu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luisa Bellu. Luisa Bellu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cerretti, Giulia, Alberto Bosio, Mario Caccese, et al.. (2025). Bevacizumab in recurrent glioblastoma: does dose matter? Our monocentric and comparative experience. Journal of Neuro-Oncology. 173(2). 449–456. 1 indexed citations

Loiacono, Daniele, F. Lobefalo, Giacomo Reggiori, et al.. (2024). Deep learning‐based optimization of field geometry for total marrow irradiation delivered with volumetric modulated arc therapy. Medical Physics. 51(6). 4402–4412. 1 indexed citations

Franceschini, Davide, Ciro Franzese, Tiziana Comito, et al.. (2024). Definitive results of a prospective non-randomized phase 2 study on stereotactic body radiation therapy (sbrt) for medically inoperable lung and liver oligometastases from breast cancer. Radiotherapy and Oncology. 195. 110240–110240. 4 indexed citations

Tropeano, Maria Pia, Zefferino Rossini, Andrea Franzini, et al.. (2024). Supramaximal resection: retrospective study on IDH-wildtype Glioblastomas based on the new RANO-Resect classification. Acta Neurochirurgica. 166(1). 196–196. 10 indexed citations

Navarria, Pierina, Federico Pessina, Giuseppe Minniti, et al.. (2023). Multimodal Treatments for Brain Metastases from Renal Cell Carcinoma: Results of a Multicentric Retrospective Study. Cancers. 15(5). 1393–1393. 2 indexed citations

Franceschini, Davide, Maria Ausilia Teriaca, Ciro Franzese, et al.. (2023). Stereotactic radiation therapy for oligometastatic esophagogastric adenocarcinoma: outcome and prognostic factors. British Journal of Radiology. 96(1144). 20220771–20220771.

Navarria, Pierina, Federico Pessina, Elena Clerici, et al.. (2023). P03.12.A PHASE III RANDOMIZED TRIAL COMPARING PREOPERATIVE HYPOFRACTIONATED RADIOSURGERY (HSRS) TO POSTOPERATIVE HYPOFRACTIONATED RADIOSURGERY (HSRS) FOR PATIENTS WITH LARGE BRAIN METASTASES SUITABLE FOR SURGICAL RESECTION SUPPORT TRIAL. Neuro-Oncology. 25(Supplement_2). ii39–ii39.

Navarria, Pierina, Elena Clerici, Luca Cozzi, et al.. (2022). Stereotactic Body Radiation Therapy for Lung Metastases From Sarcoma in Oligometastatic Patients: A Phase 2 Study. International Journal of Radiation Oncology*Biology*Physics. 114(4). 762–770. 14 indexed citations

Franzese, Ciro, Pierina Navarria, Luisa Bellu, et al.. (2022). The impact of stereotactic ablative radiotherapy on oligoprogressive metastases from renal cell carcinoma. Journal of Cancer Research and Clinical Oncology. 149(8). 4411–4417. 8 indexed citations

10.

Pessina, Federico, Pierina Navarria, Elena Clerici, et al.. (2021). Role of 11C Methionine Positron Emission Tomography (11CMETPET) for Surgery and Radiation Therapy Planning in Newly Diagnosed Glioblastoma Patients Enrolled into a Phase II Clinical Study. Journal of Clinical Medicine. 10(11). 2313–2313. 11 indexed citations

11.

Navarria, Pierina, Federico Pessina, Elena Clerici, et al.. (2021). Re-irradiation for recurrent high grade glioma (HGG) patients: Results of a single arm prospective phase 2 study. Radiotherapy and Oncology. 167. 89–96. 19 indexed citations

12.

Borioli, Valeria, Giovanna Borsellino, Mario Picozza, et al.. (2021). Influence of different lipid emulsions on specific immune cell functions in head and neck cancer patients receiving supplemental parenteral nutrition: An exploratory analysis. Nutrition. 86. 111178–111178. 12 indexed citations

13.

Navarria, Pierina, Federico Pessina, Ciro Franzese, et al.. (2020). The 70-year-old newly diagnosed glioblastoma patients are older than the 65-year-old? Outcome evaluation of the two categories in a matched case control study with propensity score balancing. Radiotherapy and Oncology. 156. 49–55. 1 indexed citations

14.

Pessina, Federico, Pierina Navarria, Luisa Bellu, et al.. (2020). Treatment of patients with glioma during the COVID-19 pandemic: what we learned and what we take home for the future. Neurosurgical FOCUS. 49(6). E10–E10. 12 indexed citations

15.

Lombardi, Giuseppe, Mattia Barbot, Filippo Ceccato, et al.. (2020). Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature. Pituitary. 23(4). 359–366. 25 indexed citations

16.

Caccese, Mario, Marta Padovan, Domenico D’Avella, et al.. (2020). Anaplastic Astrocytoma: State of the art and future directions. Critical Reviews in Oncology/Hematology. 153. 103062–103062. 12 indexed citations

17.

Lombardi, Giuseppe, Gian Luca De Salvo, Alba A. Brandes, et al.. (2018). Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. The Lancet Oncology. 20(1). 110–119. 257 indexed citations breakdown →

18.

Lombardi, Giuseppe, Mario Caccese, Luisa Bellu, et al.. (2018). Good tolerability of maintenance temozolomide in glioblastoma patients after severe hematological toxicity during concomitant radiotherapy and temozolomide treatment. Anti-Cancer Drugs. 29(9). 924–928. 1 indexed citations

19.

Lombardi, Giuseppe, Ardi Pambuku, Luisa Bellu, et al.. (2017). Effectiveness of antiangiogenic drugs in glioblastoma patients: A systematic review and meta-analysis of randomized clinical trials. Critical Reviews in Oncology/Hematology. 111. 94–102. 70 indexed citations

20.

Lombardi, Giuseppe, Luisa Bellu, Ardi Pambuku, et al.. (2016). Clinical outcome of an alternative fotemustine schedule in elderly patients with recurrent glioblastoma: a mono-institutional retrospective study. Journal of Neuro-Oncology. 128(3). 481–486. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact